REG - Renalytix PLC - Growing collaboration with NYKHM

RenalytixAnnouncement

03/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250603:nRSC1008La&default-theme=true

RNS Number : 1008L  Renalytix PLC  03 June 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET
ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO
THE EUROPEAN UNION (WITHDRAWAL) ACT 2018
("MAR").

 
Renalytix plc

("Renalytix" or the "Company")

 

Growing collaboration with New York Kidney & Hypertension Medicine

 

Renalytix collaborates with NYKHM to bring kidneyintelX.dkd testing to
underserved communities

in the Greater New York area, enabling access for over 2,000 patients

 

LONDON and NEW YORK, 3 June 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a
precision medicine company, announces a collaboration with New York Kidney
& Hypertension Medicine (NYKHM) to expand access to kidneyintelX.dkd, the
only FDA-approved and Medicare reimbursed prognostic test to support
early-stage risk assessment in patients with type 2 diabetes and chronic
kidney disease stages 1-3b.

 

NYKHM is a national leader in applying EHR-integrated analytics and
comprehensive, personalized treatment plans to manage chronic kidney disease
in  communities across Queens, Brooklyn, and the greater New York
metropolitan area. The Renalytix-NYKHM collaboration will expand the use of
kidneyintelX.dkd blood testing in underserved, high-risk communities to
mitigate progressive decline in kidney function and help preserve patient
health and quality of life. The program is expected to enable access to over
2,000 patients for kidneyintelX.dkd prognostic blood testing, complementing
Renalytix expanded access programs throughout the Northeast region.

 

Enhanced insight into kidney function can help NYKHM physicians and their
patients develop personalized treatment plans to reduce the risk of kidney,
cardiovascular, and metabolic disease, further enabling long-term wellness.
The kidneyintelX.dkd test is FDA-approved, reimbursed by Medicare, and
recommended in international kidney disease clinical guidelines.

 

As part of the collaboration, Renalytix and NYKHM will also engage in:

 

·    Community-Based Provider Education: Coordinating joint educational
sessions for primary care physicians to promote early-stage CKD detection and
risk stratification.

 

·      Patient Awareness Initiatives: Launching a public-facing campaign
to educate patients about kidney disease risk factors and the importance of
proactive management.

 

Dr. Premila Bhat, Partner, NYKHM and Managing Partner, Tidal Dialysis, LLC,
said: "We are dedicated to bringing the latest medical innovations to our
communities to ensure that our patients with chronic kidney disease can take
charge of their health and wellness. The kidneyintelX.dkd test enables both
physicians and patients to understand kidney disease risk early, so we can
take timely action and deliver the most effective care available today."

 

James McCullough, CEO of Renalytix, commented: "Dr. Bhat and her team
represent exactly the type of forward-thinking, patient-centered partners with
whom we want to align. This partnership is a clear demonstration of how early
prognosis, combined with community-based care, can shift the paradigm toward
earlier detection and better outcomes in kidney disease."

 

The person responsible for arranging for the release of this announcement on
behalf of Renalytix is James McCullough, CEO.

 

 

For further information, please contact:

 

 Renalytix plc                                                          www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                                  Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)                            Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Fred Walsh / Brough Ransom / Ben Good

 Oberon Capital (Joint Broker)                                          Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                                                    Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                                          Mob: 07980 541 893 / 07407 804 654

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

Unrecognized and uncontrolled kidney disease remains one of the largest
barriers to controlling cost and suffering in the United States and the United
Kingdom's medical system, affecting over 14 million and 8 million people,
respectively. After five years of development and clinical validation,
kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic
tool capable of understanding a patient's risk with kidney disease early where
treatment has maximal effect. kidneyintelX.dkd is now being deployed across
large physician group practices and health systems in select regions of the
United States.

 

The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by Medicare,
the largest insurance payer in the United States, at $950 per reportable
result. kidneyintelX.dkd is also recommended for use in the international
chronic kidney disease clinical guidelines (KDIGO).

 

KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix.

 

About New York Kidney & Hypertension Medicine (www.nykhm.com )

New York Kidney & Hypertension Medicine (NYKHM) was established in 1988 to
serve the populations of Brooklyn and Queens in New York City. Their goal is
to transform diagnosis, risk stratification and CKD care delivery for patients
in a seamless fashion.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQLLFBEQLXBBK